An update of phase 2 trial results: Patients with recurrent malignant glioma treated with iodine 131-labeled murine antitenascin monoclonal antibody 81C6 into the resection cavity
Publication
, Conference
Reardon, D; Akabani, G; Friedman, A; Friedman, H; McLendon, R; Quinn, J; Rich, J; Vredenburgh, J; Zalutsky, M; Bigner, D
Published in: NEURO-ONCOLOGY
July 1, 2005
Duke Scholars
Published In
NEURO-ONCOLOGY
ISSN
1522-8517
Publication Date
July 1, 2005
Volume
7
Issue
3
Start / End Page
311 / 311
Location
Edinburgh, SCOTLAND
Publisher
DUKE UNIV PRESS
Conference Name
2nd Quadrennial Meeting of the World-Federation-of-Neuro-Oncology/6th Meeting of the European-Association-for-Neur-Oncology
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Reardon, D., Akabani, G., Friedman, A., Friedman, H., McLendon, R., Quinn, J., … Bigner, D. (2005). An update of phase 2 trial results: Patients with recurrent malignant glioma treated with iodine 131-labeled murine antitenascin monoclonal antibody 81C6 into the resection cavity. In NEURO-ONCOLOGY (Vol. 7, pp. 311–311). Edinburgh, SCOTLAND: DUKE UNIV PRESS.
Reardon, D., G. Akabani, A. Friedman, H. Friedman, R. McLendon, J. Quinn, J. Rich, J. Vredenburgh, M. Zalutsky, and D. Bigner. “An update of phase 2 trial results: Patients with recurrent malignant glioma treated with iodine 131-labeled murine antitenascin monoclonal antibody 81C6 into the resection cavity.” In NEURO-ONCOLOGY, 7:311–311. DUKE UNIV PRESS, 2005.
Reardon D, Akabani G, Friedman A, Friedman H, McLendon R, Quinn J, et al. An update of phase 2 trial results: Patients with recurrent malignant glioma treated with iodine 131-labeled murine antitenascin monoclonal antibody 81C6 into the resection cavity. In: NEURO-ONCOLOGY. DUKE UNIV PRESS; 2005. p. 311–311.
Reardon, D., et al. “An update of phase 2 trial results: Patients with recurrent malignant glioma treated with iodine 131-labeled murine antitenascin monoclonal antibody 81C6 into the resection cavity.” NEURO-ONCOLOGY, vol. 7, no. 3, DUKE UNIV PRESS, 2005, pp. 311–311.
Reardon D, Akabani G, Friedman A, Friedman H, McLendon R, Quinn J, Rich J, Vredenburgh J, Zalutsky M, Bigner D. An update of phase 2 trial results: Patients with recurrent malignant glioma treated with iodine 131-labeled murine antitenascin monoclonal antibody 81C6 into the resection cavity. NEURO-ONCOLOGY. DUKE UNIV PRESS; 2005. p. 311–311.
Published In
NEURO-ONCOLOGY
ISSN
1522-8517
Publication Date
July 1, 2005
Volume
7
Issue
3
Start / End Page
311 / 311
Location
Edinburgh, SCOTLAND
Publisher
DUKE UNIV PRESS
Conference Name
2nd Quadrennial Meeting of the World-Federation-of-Neuro-Oncology/6th Meeting of the European-Association-for-Neur-Oncology
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences